Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.

Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.
R
R

Regeneron

Ειδήσεις

Reuters - 1 εβδομάδα πριν

Regeneron Pharmaceuticals Says Results For Q2 To Include Acquired In-Process Research & Development Charge Of About $24 Mln On A Pre-Tax Basis

BRIEF-Regeneron Pharmaceuticals Says Results For Q2 To Include Acquired In-Process Research & Development Charge Of About $24 Mln On A Pre-Tax Basis July 8 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS INC - RESULTS FOR Q2 TO INCLUDE ACQUIRED IN-PROCESS RESEARCH & DEVELOPMENT CHARGE OF ABOUT $24 MILLION ON A PRE-TAX B
R
Reuters - 2 εβδομάδες πριν

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 2 εβδομάδες πριν

EU approves Sanofi's Dupixent for 'smoker's lungs'

EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi SASY.PA and partner Regeneron REGN.O on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States. The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a re
R
S
Reuters - 2 εβδομάδες πριν

US drugmakers fall as Biden urges price cuts on obesity drugs

BUZZ-US drugmakers fall as Biden urges price cuts on obesity drugs ** Shares of U.S. drugmakers down between 1% and 2% after President Joe Biden and Senator Bernie Sanders, in an opinion piece on USA Today, called out Eli Lilly LLY.N and Novo Nordisk NOVOb.CO to reduce high costs of their weight loss drugs ** They also pointed to high prices of all medicines across the United States compared to other nations ** U.S.
A
G
P
R
Reuters - 3 εβδομάδες πριν

Verona prices lung disease therapy above expectations at $2,950/month

UPDATE 3-Verona prices lung disease therapy above expectations at $2,950/month Adds company comment in paragraph 6 By Pratik Jain June 27 (Reuters) - Verona Pharma VRNA.O said on Thursday its therapy for a chronic and potentially fatal lung disease will have a wholesale price of $2,950 per month, above the estimated cost-effectiveness range by a drug-pricing watchdog.
R
S
Reuters - 3 εβδομάδες πριν

US FDA approves Verona Pharma's inhaled COPD therapy

UPDATE 2-US FDA approves Verona Pharma's inhaled COPD therapy Adds shares, adds analyst comment in paragraphs 9 and 10, management comment in paragraph 11 By Pratik Jain and Sruthi Narasimha Chari June 26 (Reuters) - The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
R
S
Reuters - 3 εβδομάδες πριν

FDA approves Verona Pharma's therapy for 'smoker's lungs'

FDA approves Verona Pharma's therapy for 'smoker's lungs' June 26 (Reuters) - The U.S. Food and Drug Administration has given its approval for a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. Reporting by Pratik Jain and Sruthi Narasimha Chari in Bengaluru; Edi
R
S
Reuters - 3 εβδομάδες πριν

Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia

Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia By Michael Erman NEW YORK, June 26 (Reuters) - A top Bayer BAYGn.DE pharmaceutical executive said on Wednesday his group will continue slashing managerial jobs this year, planning cuts in Germany, Japan, the United Kingdom, Belgium and the Netherlands as part of the company's internal reorganization.
B
R
Reuters - 4 εβδομάδες πριν

Teva in talks to settle US lawsuit alleging MS drug kickbacks

Teva in talks to settle US lawsuit alleging MS drug kickbacks By Nate Raymond BOSTON, June 17 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA said it is in active talks to settle a U.S. Department of Justice lawsuit alleging it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone.
R
T
Reuters - 4 εβδομάδες πριν

Regeneron Pharmaceuticals Says At 14-Months Median Follow-Up In Trial, 50% Of Patients Achieved A Complete Response Or Better, A 71% Overall Response Rate

BRIEF-Regeneron Pharmaceuticals Says At 14-Months Median Follow-Up In Trial, 50% Of Patients Achieved A Complete Response Or Better, A 71% Overall Response Rate June 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : UPDATED LINVOSELTAMAB DATA SHOWCASE CONTINUED DEEPENING OF RESPONSES IN PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA REGENER
R
Reuters - 1 μήνα πριν

Replimune rallies after $100 mln PIPE financing

BUZZ-Replimune rallies after $100 mln PIPE financing ** Shares of Replimune Group REPL.O up 8.3% at $9.55 on Thurs after biotech firm raises $100 mln in private placement ** REPL now up 6 out of past 7 sessions, racking up ~90% gain along the way ** Co early Thurs said will sell ~5.7 mln shares at $8.82 and pre-funded warrants to buy ~5.7 mln shares at $8.819/warrant in a PIPE (private investment in public equity) ** Financing led by a life-sciences focused institutional investor, with participa
R
Reuters - 1 μήνα πριν

U.S. BioNTech, Honeywell International, Klaviyo

U.S. RESEARCH ROUNDUP-BioNTech, Honeywell International, Klaviyo June 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biontech, Honeywell International and Klaviyo, on Wednesday. HIGHLIGHTS * BioNTech SE BNTX.O : JP Morgan raises target price to $94 from $90 * Honeywell International Inc HON.O : HSBC raises target price to $235 from $200 * Klaviyo Inc KVYO.N : Barclays raises to overweight from equal weight * NetA
A
F
G
N
R
G
D
M
Reuters - 1 μήνα πριν

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V
Reuters - 1 μήνα πριν

U.S. Honeywell International, Stericycle, Target Corp

CORRECTED-U.S. RESEARCH ROUNDUP-Honeywell International, Stericycle, Target Corp Corrects Elf Beauty entry to say TD Cowen raises, not cuts, target price to $235 from $190 June 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, including Honeywell International, Stericycle and Target Corp on Tuesday.
A
B
M
N
Q
R
S
S
T
I
S
Reuters - 2 μήνες πριν

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review

UPDATE 1-EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review Adds details from EMA disclosure and background throughout May 31 (Reuters) - Sanofi SASY.PA and partner Regeneron Pharmaceuticals REGN.O have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review.
R
S
Reuters - 2 μήνες πριν

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung' May 31 (Reuters) - French drugmaker Sanofi SASY.PA and its partner Regeneron REGN.O said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain patients 'smoker's lung', or COPD.
R
S
Reuters - 2 μήνες πριν

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch May 31 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. RENAULT RENA.PA The French automaker and Chinese peer Geely on Friday announced the creation of a 50-50 joint venture for hybrid and combustion powertrain components and systems.
R
R
S
T
V
F
N
U
Reuters - 2 μήνες πριν

Regeneron Pharmaceuticals Says European Commission Is Expected To Announce Final Decision On Dupixent Application In Coming Months.

BRIEF-Regeneron Pharmaceuticals Says European Commission Is Expected To Announce Final Decision On Dupixent Application In Coming Months. May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : DUPIXENT® (DUPILUMAB) RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT PATIENTS WITH COPD EUROPEAN COMMISSION IS EXPECTED TO ANNOUNCE A FINAL DECISION ON DUPIXENT APPLICATION IN COMING MONTHS.
R
S
Reuters - 2 μήνες πριν

Sanofi: FDA Extends Review Of Dupixent For Treatment Of COPD Patients

BRIEF-Sanofi: FDA Extends Review Of Dupixent For Treatment Of COPD Patients May 31 (Reuters) - Sanofi SA SASY.PA : UPDATE ON FDA PRIORITY REVIEW OF DUPIXENT FOR TREATMENT OF COPD PATIENTS WITH TYPE 2 INFLAMMATION US FOOD AND DRUG ADMINISTRATION (FDA) HAS EXTENDED BY THREE MONTHS TARGET ACTION DATE OF ITS PRIORITY REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR DUPIXENT (DUPILUMAB) REVISED TARGET ACTION DATE IS SEPTEMBER 27, 2024 FDA DID NOT RAISE ANY CONCERNS REGARDING APPROVABIL
R
S
Reuters - 2 μήνες πριν

Regeneron Issues Update On FDA Priority Review Of Dupixent

BRIEF-Regeneron Issues Update On FDA Priority Review Of Dupixent May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : UPDATE ON FDA PRIORITY REVIEW OF DUPIXENT® (DUPILUMAB) FOR THE TREATMENT OF COPD PATIENTS WITH TYPE 2 INFLAMMATION FDA DID NOT RAISE ANY CONCERNS REGARDING APPROVABILITY OF DUPIXENT FOR THIS INDICATION. REVISED TARGET ACTION D
R
S

Όροι

Δημοφιλή περιουσιακά στοιχεία

Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.

Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.

Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.

Προειδοποίηση ρίσκου: Τα κεφάλαιά σας κινδυνεύουν. Τα προϊόντα με μόχλευση ενδέχεται να μην είναι κατάλληλα για όλους. Παρακαλούμε λάβετε υπόψη σας τη Γνωστοποίηση ρίσκου.